Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/blau syndrome: Its possible action and mechanism

Arthritis and Rheumatism

Volumn 62, Issue 1, 2010, Pages 250-257

  Yasui, Kozo ^a   Yashiro, Masato ^a   Tsuge, Mitsuru ^a   Manki, Akira ^a   Takemoto, Kei ^a   Yamamoto, Michiko ^a   Morishima, Tsuneo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLONY STIMULATING FACTOR 1; CYCLOSPORIN; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 4; METHOTREXATE; MURAMYL DIPEPTIDE; PREDNISOLONE; STROMELYSIN; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTHRALGIA; ARTHRITIS; ARTICLE; BLAU SYNDROME; CASE REPORT; CELL ISOLATION; CELL SURVIVAL; CHILD; CONTROLLED STUDY; COXITIS; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; EYE EXAMINATION; FEMALE; FEVER; FINGER; GENETIC ANALYSIS; GENOTYPE; GIANT CELL; HAND; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KNEE ARTHRITIS; LABORATORY; LEUKOCYTE COUNT; LOW BACK PAIN; MALE; MISSENSE MUTATION; MONOCYTE; OPTIC NERVE; OSTEOCLAST; PAPILLITIS; PRIORITY JOURNAL; SARCOIDOSIS; SCHOOL CHILD; SKIN DEFECT; SYMPTOM; TREATMENT RESPONSE; VISUAL ACUITY;

ADOLESCENT; ARTHROGRAPHY; CELLS, CULTURED; CHILD; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MUTATION, MISSENSE; NF-KAPPA B; NOD2 SIGNALING ADAPTOR PROTEIN; REMISSION INDUCTION; SARCOIDOSIS; THALIDOMIDE;

EID: 74849116666     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.25035     Document Type: Article

References (26)

1. Hetherington S. Sarcoidosis in young children. Am J Dis Child 1982;136:13-5.
2. Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective [review]. Clin Pediatr (Phila) 1998;37:707-17.
3. Fink CW, Cimaz R. Early onset sarcoidosis: not a benign disease. J Rheumatol 1997;24:174-7.
4. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-κB activation: common genetic etiology with Blau syndrome. Blood 2005;105:1195-7.
5. Rose CD, Wouters CH, Meiorin S, Doyle TM, Davey MP, Rosenbaum JT, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006;54:3337-44.
6. Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998;134:1045-6.
7. Oliver SJ, Kikuchi T, Krueger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002;102:225-36.
8. Baughman RP, Loer EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 2007;25:334-40.
9. Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, Yamazaki S, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009;60:242-50.
10. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
11. Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98:2544-54.
12. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107:3098-105.
13. Nakao A, Fukushima H, Kajiya H, Ozeki S, Okabe K. RANKL-stimulated TNFα production in osteoclast precursor cells promotes osteogenesis by modulating RANK signaling pathways. Biochem Biophys Res Commun 2007;357:945-50.
14. Ferrero D, Pessano S, Pagliardi GL, Rovera G. Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies. Blood 1983;61:171-9.
15. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Terminal differentiation of human promyelocytic leukemia cells induced by dimethylsufoxide and other polar compounds. Proc Natl Acad Sci U S A 1979;75:2458-62.
16. Okamoto H, Mizuno K, Horio T. Monocyte-derived multinucleated giant cells and sarcoidosis. J Dermatol Sci 2003;31:119-28.
17. Fallon MD, Perry HM III, Teitelbaum SL. Skeletal sarcoidosis with osteopenia. Metab Bone Dis Relat Res 1981;3:171-4.
18. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;1:1358.
19. Mellin GW, Katzenstein M. The saga of thalidomide. I. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962;267:1184-92.
20. Lentz W. Thalidomide and congenital abnormalities. Lancet 1962;1:45.
21. Bessis D, Guillot B, Monpoint S, Dandurand M, Guilhou JJ. Thalidomide for systemic lupus erythematosus. Lancet 1992;339:549-50.
22. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999;20:538-40.
23. Kaplan G, Thomas S, Fierer DS, Mulligan K, Haslett PA, Fessel WJ, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000;16:1345-55.
24. Dredge K, Marriot JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 2002;22:425-37.
25. 2, but not that activated by ceralide, lipopolysaccharides, or phorbol ester. J Immunol 2002;168:2644-51.
26. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.